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Abstract
Background: Prescribing in dental practice has a relatively small but important contribution to the quantity of
antibiotics prescribed in primary care. This study aimed to analyse antibiotic prescribing in dentistry over time
(2010–2016) in 4 different Northern European countries and their relative contribution to national outpatients
consumption.
Methods: This retrospective study evaluated the frequency and number of national antibiotic prescriptions written
by dentists in England, Scotland, Norway and Sweden. The consumption of such antibiotics was measured using
WHO defined daily doses (DDDs), DDDs per 100,000 inhabitants per day (DIDs100,000).
Results: A total of more than 27 million prescriptions (27,026,599) archived between 2010 and 2016 from the four
countries were analysed. The national contribution of Norwegian dentists to the total primary care prescription
during this period was 8%. The corresponding figures for Sweden, Scotland and England were 7, 6, and 8%. Dental
contribution to National antibiotic use in all four countries has decreased over the study time period for commonly
prescribed antibiotics in dentistry, i.e., the beta-lactams (Phenoxymethyl penicillin/Amoxicillin) and metronidazole.
There were less numbers of prescriptions by dentists in Norway and Sweden compared to England and Scotland.
Marked differences in some classes of antibiotics were noted with Phenoxymethyl penicillin dominating in Sweden/
Norway compared to Amoxicillin and Metronidazole in England/Scotland. In England and Scotland, dentists were
the largest prescribers of metronidazole in primary care. Clindamycin prescriptions was higher in Norway and
Sweden.
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Conclusion: Noticeable differences exist in prescribing patterns for the management of oral infections. High levels
of metronidazole use in England and Scotland also require further analysis. All countries over the study period
showed a decrease in total numbers of antibiotics prescribed.
Keywords: Dentistry, Prescriptions, Antibiotics, Consumption, Defined daily doses (DDD), Phenoxymethyl penicillin,
Amoxicillin, Metronidazole, Clindamycin, Spiramycin
Background
Prescribing in dental practice has a relatively small but
important contribution to the quantity of antibiotics pre-
scribed in primary care. Dentists prescribe antibiotics to
treat acute bacterial intra-oral infections and some cases
of chronic periodontitis. The majority of acute dento-
alveolar infections should be managed primarily by sur-
gical or local measures to control the source of infection
(extraction, root canal therapy or incision and drainage)
with professional guidelines re-enforcing this basic tenet
of infection source control in dental practice [1–3].
However, there is evidence that there has been both in-
appropriate qualitative and quantitative prescribing for
dental infections [4–9].
The trend of antibiotic prescriptions over time is influ-
enced by many factors, such as disease levels, access to
dental services, prescribing guidelines, patients’ attitude
toward antibiotic prescribing, and incidence of antimicro-
bial resistance (AMR) [6, 10]. The prevalence of untreated
dental caries and severe periodontal diseases, which could
lead to dento-alveolar infections can be described in terms
of Years Lived with Disability (YLD) standardised rate per
capita, which was highest in Scotland (0.579), followed by
England (0.51), Norway (0.481) and then Sweden (0.473)
[11]. Accurate estimations of AMR in bacterial popula-
tions isolated from acute dental infections are difficult to
interpret. Review articles have reported resistance rates to
vary between 9 and 54% [12]. The AMR data is con-
founded by changes in bacterial taxonomy, methods of
susceptibility testing and breakpoints used. With increas-
ing trends of antibiotic resistant infections across many
bacterial species and clinical specialties, adoption of anti-
microbial stewardship principles by all prescribers is vital.
In addition, it is timely to remember that dental antibiotic
use contributes to the selection pressure for development
of AMR generally and not just linked to dental infections
or oral pathogens [13–15]. An important principle of anti-
microbial stewardship is surveillance of antibiotic use
and feedback to prescribers to drive quality improve-
ment in the empirical use of antibiotics [16]. National
data on antibiotic use by dentists can be used to
identify priorities for antibiotic stewardship in dentis-
try and inform management and prescribing guidance.
There are some reports of good outcomes following a
variety of interventions [17].
The objective of this study was to compare the na-
tional use of antibiotics by dental prescribers in England
and Scotland with Norway and Sweden. Report their
relative contribution to the total national antibiotic con-
sumption by outpatients, and review differences in pre-
scribing patterns to ascertain whether lessons can be
used to inform antimicrobial stewardships policies in the
four countries.
Methods
Data source
For the study period 2010–2016, except for England
where data was available from 2011, the data on Na-
tional Health Service (NHS) antibiotic prescriptions
written by dentists dispensed in the community was ob-
tained from the NHS Business Service Authority for
England and from the Prescribing Information System, a
database of all NHS prescriptions dispensed in Scotland
held by NHS National Services Scotland. The data on
dental antibiotic use in Norway, was obtained from the
Norwegian prescription database (NorPD) [18], while
the dental antibiotic use from Sweden was obtained
from the Public Health Agency of Sweden. The aggre-
gated data from the four countries also include the num-
ber of dentists practicing in NHS England and NHS
Scotland and all dentists practicing in Norway and
Sweden. Obtaining of the anonymous aggregated data
on antibiotic use by dentists was approved by the re-
spective authorities in each country.
Classification of data
The data obtained on antibiotic use was classified ac-
cording to the anatomical therapeutic chemical (ATC)
classification system, using the WHO defined daily dose
(DDD) for each drug [19]. In this system, antibiotics for
systemic use fall into ATC group “J01” except for metro-
nidazole where it falls into ATC group “P01”. The data
included the number of antibiotic prescription items
written by dentists dispensed in the community to each
antibiotic, total national antibiotic use expressed as
DDD in the country in each year and the DDD pre-
scribed by dentists for each respective year. Antibiotic
use by dentists as a proportion of total antibiotic use in
the community was calculated.
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Antibiotic groups
In the current study, all dental prescriptions dispensed
in the community were analysed. In dentistry, the use of
antibiotics to treat dental and oral infections usually re-
lies on five groups of antibiotics. These are beta-lactams
(primarily Phenoxymethyl penicillin and amoxicillin),
macrolides, lincosamides, tetracyclines, and metronida-
zole. Beta-lactams: Amoxicillin, ATC code J01CA04;
Phenoxymethyl penicillin (penicillin V), ATC code
J01CE02; Co-amoxiclav (Augmentin), J01CR02, Cefa-
lexin, ATC codes J01DB01 and Cefradine, ATC code
J01DB09. Macrolides and Lincosamides: Erythromycin,
ATC code J01FA01; Spiramycin, ATC code J01FA02;
Clarithromycin, ATC code J01FA09; Azithromycin, ATC
code J01FA10; Clindamycin, ATC code J01FF01. Tetra-
cyclines: Doxycycline, ATC code J01AA02; Oxytetracyc-
line, ATC code J01AA06 and Tetracycline, ATC code
J01AA07. Metronidazole: Metronidazole, ATC code
P01AB01.
Comparison of antibiotic consumptions attributed to
dental prescription between England, Scotland, Norway
and Sweden
Trends in the consumption of antibiotics were assessed
for the study period (2010–2016). The proportion of
each antibiotic prescribed compared to the total anti-
biotic prescription by dentists was calculated. The pro-
portion of antibiotic consumption attributed to
dentistry-based prescription to the total national primary
care consumption was also calculated. The mid-year
populations in England and Scotland for each year were
extracted from the office of National Statistics. The
population size in Norway and Sweden for each year was
obtained from the Statistical Bureau in Norway and
Sweden. To better illustrate the consumption of antibi-
otics by dental prescriptions in the four countries, the
data was calculated for each antibiotic prescribed by
dentists in each country and expressed as a number of
DDD per 100,000 inhabitants per day (DID100,000). The
average number of antibiotic prescriptions dispensed in
the community per dentist per year in each country was
calculated. The proportion (%) of each antibiotic to the
total antibiotics dispensed in the community was also
calculated.
Results
A total of 21,719,095 dental prescriptions were dis-
pensed in England, 2,591,077 Scotland, 1,048,568
Norway and 1, 717,859 were in Sweden, during the study
period. The number of prescriptions issued by dentists
per year in England, Scotland, Norway and Sweden are
listed in Table 1 and the average prescription per dentist
per year in Norway and Sweden versus England and
Scotland is presented in Fig. 1.
The highest annual rate of antibiotic prescribing per
dentist was in England in 2011 (n = 171), by 2016 this
had declined to 133 antibiotic prescriptions per year
(Fig. 1), this represented the highest number of prescrip-
tions per dentist from all four countries. In Scotland the
prescription rate per dentist peaked in 2012 (n = 119)
and had declined to 87 per annum by 2016. Norway had
the lowest rates of prescriptions per dentist (peaking at
31 in 2014) with a decline in prescriptions to 26 per year
by 2016. Swedish prescribing levels were highest in 2010
(n = 36) and declined to 28 per annum by 2016. The
dental contribution to the total of antibiotics prescribed
in the community for each Country over the period
2010–16 was 8, 6, 8, and 7% for England, Scotland,
Norway and Sweden. The proportion (%) of Phenoxy-
methyl penicillin and Amoxicillin dispensed in Norway
and Sweden versus England and Scotland by dentists to
the total antibiotics dispensed in the community by gen-
eral dental practitioners is presented in Fig. 2.
The proportion (%) of Metronidazole and Clindamycin
dispensed in Norway and Sweden versus England and
Scotland to the total antibiotics dispensed by general
dental practitioners is presented in Fig. 3.
The DID100,000 attributed to dental prescriptions in
England, Scotland, Norway and Sweden in every year
from 2010 to 2016 are presented in Table 2. Table 3 pre-
sents the average DID100,000 attributed to dental pre-
scriptions in the study period.
Analysis of each antibiotic prescribed for dental
infections over time
There were marked differences in patterns of consump-
tion of antibiotic attributed to dental prescription be-
tween England and Scotland versus Norway and
Sweden. In England and Scotland, Amoxicillin, Metro-
nidazole, Erythromycin and Phenoxymethyl penicillin
(ordered from highest to lowest) were the top four anti-
biotics prescribed by dentists. However, in Norway and
Sweden, Phenoxymethyl penicillin, Amoxicillin, Clinda-
mycin and then Metronidazole (ordered from highest to
lowest) were the top four antibiotics prescribed by
dentists.
Phenoxymethyl penicillin (penicillin V) consumption
This was the most commonly prescribed antibiotic in
Norway and Sweden by dental practitioners. In line with
the overall decrease in total antibiotic prescriptions be-
tween 2010 and 2016 there was a trend towards decrease
in the DID100,000 for Phenoxymethyl penicillin. Sweden
had the highest reduction (16%) in DID100,000 of this
antibiotic declining to 66.86 in 2016 from 80.37 in 2010.
This was followed by Norway (14% reduction) with a
DID100,000 of 68.49 in 2010 declining to 58.65 in 2016. In
contrast, Phenoxymethyl penicillin was one of the least
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commonly prescribed antibiotics by dental practitioners in
England and Scotland over the study period. For England
in 2011 the DID100,000 was 0.94 falling to 0.29 in 2016 and
in Scotland a fall from 2.02 in 2010 to 0.68 in 2016.
Amoxicillin consumption
Amoxicillin was prescribed more frequently in England and
Scotland than in Norway and Sweden. The highest number
of DID100,000 was in England in 2011 (n = 89.93) declining
to 80.93 in 2016. In contrast the Amoxicillin DID100,000 in
Scotland rose from 70.28 in 2010 to 82.92 in 2016. Sweden
saw a fall in DID100,000 from 10.28 to 6.99 in 2016. Con-
versely, Norway saw an increase in the DID100,000 between
2010 (n = 7.57) rising to a DID100,000 of 9.52 in 2016.
Metronidazole consumption
For England and Scotland Metronidazole was the second
most frequently prescribed antibiotic, with a DID100,000
in 2011 of 13.66 for England and in Scotland peaking at
a DID100,000 of 11.96 in 2012 and falling to 9.56 in 2016.
Both England and Scotland prescribed more Metronida-
zole than Norway and Sweden. In Norway and Sweden,
this was the fourth most frequently prescribed antibiotic
(after Phenoxymethyl penicillin, Amoxicillin and Clinda-
mycin). The Metronidazole DID100,000 for Sweden and
Norway both showed deceases over the 2010 and 2016
period with Sweden showing a decline in DID100,000 of
3.29 in 2010 to 2.52 in 2016 and Norway’s DID100,000 de-
creasing from 3.52 in 2010 to 3.39 in 2016.
Erythromycin consumption
In England and Scotland this was the third most com-
monly prescribed antibiotic but the fifth most commonly
prescribed antibiotic in Norway and Sweden (after Phe-
noxymethyl penicillin, amoxicillin, clindamycin and
metronidaxole). All countries showed a decline in
Table 1 Total number of prescriptions for antibiotics dispensed in the community by dentists (Prescriptions), total number of
dentists (dentists) and average prescription by dentists (average prescription per dentist)
Year England Scotland Norway Sweden
No. of prescriptions/No. of dentists (Average prescription per dentists)
2010 3,850,773/22799 (169) 367,268/3396 (108) 146,672/5121 (29) 268,539/7509 (36)
2011 3,913,551/22920 (171) 395,238/3466 (114) 149,161/5183 (29) 272,291/7630 (36)
2012 3,907,934/23201 (168) 411,207/3454 (119) 152,027/5223 (29) 266,824/7710 (35)
2013 3,790,869/23723 (160) 394,998/3602 (110) 153,993/5134 (30) 246,454/7731 (32)
2014 3,682,513/23947 (154) 369,066/3604 (102) 155,644/5102 (30) 225,820/7777 (29)
2015 3,425,450/24089 (142) 335,136/3610 (93) 150,827/5256 (30) 221,383/7699 (29)
2016 3,190,045/ 24,007 (133) 318,164/3670 (87) 140,244/5334 (26) 216,548/7700 (28)
Mean ± SD (95%CI)
156.71 ± 14.60 (156.71 ± 10.81) 104.71 ± 11.45 (104.71 ± 8.48) 29 ± 1.41 (29 ± 1.048) 32.14 ± 3.53 (32.14 ± 2.61)
Fig. 1 Average number of antibiotic prescriptions dispensed in the community per dentist per year in Norway, Sweden, England and Scotland
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erythromycin prescriptions over the study period with
the largest DID100,000 in England (n = 6.16) in 2011 and
the lowest DID100,000 in Sweden in 2016 of 0.21.
Clindamycin consumption
Norway and Sweden had the highest DID100,000 con-
sumption for Clindamycin, with a DID100,000 of 4.03 in
2010 for Norway rising to 4.58 in 2016 and from a
DID100,000 of 4.15 in 2010 to 3.02 in 2016 for Sweden. In
contrast the Clindamycin consumption were lower for
England and Scotland varying from a 0.45 DID100,000 in
England in 2011 to 0.19 DID100,000 in 2016 for Scotland.
Other antibiotics consumption
The Tetracycline class of antibiotics were prescribed at
approximately the same DID100,000 levels across the four
countries. In contrast, for Norway the DID100,000 for Azi-
thromycin (0.8 in 2016) and Spiramycin (0.1 in 2016)
was higher than in the other three countries. The
DID100,000 for Augmentin (Co-amoxiclav) prescriptions
was significantly higher in England and Scotland in 2016
running at 0.4 and 0.13, respectively.
Discussion
The Global Burden of Disease Study 2016 estimated that
oral diseases affected half of the world’s population [20].
Untreated dental decay, which could lead to dento-
alveloar infections, in permanent teeth affects 2.3 billion
people, and untreated dental decay in primary teeth af-
fects more than 560 million children worldwide. Severe
periodontal diseases that may result in tooth loss and
affect general health and wellbeing, was estimated to be
the 11th most prevalent disease globally [20]. Dentists
prescribe a panel of antibiotics to treat and manage
acute dento-alveloar infections. Differences in total vol-
umes of antibiotics prescribed as well as differences in
prescription pattern in different geographical locations
to treat and manage dento-alveloar infections could be
explained by differences in dental disease patterns sus-
ceptibility/resistance profile of oral bacteria. One of the
Fig. 2 The proportion (%) of Phenoxymethyl penicillin and Amoxicillin dispensed in Norway, Sweden, England and Scotland to the total
antibiotics dispensed by the general dental practitioners. Data from England is available from 2011 to 2016
Fig. 3 The proportion (%) of Metronidazole and Clindamycin dispensed in Norway, Sweden, England and Scotland to the total antibiotics
dispensed by the general dental practitioners. Data from England is available from 2011 to 2016
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main findings of the current study is that the mean
number of prescriptions per dentist in the study period
in Norway and Sweden is 29 and 32 prescriptions, re-
spectively. In England and Scotland, the mean number
of prescriptions per dentist in the study period is 156
and 104 prescriptions, respectively. In addition, the nar-
rower spectrum Phenoxymethyl penicillin are more
widely prescribed in Norway and Sweden whilst the
broader spectrum Amoxicillin is largely prescribed in
England and Scotland. The factors that influence the dif-
ference in prescription rate between dentists in these
countries warranty further investigation.
This is the first study to use National data to assess
antibiotic prescription volume and prescription patterns
for dental infections in four northern European coun-
tries. A total of 27,076,599 prescriptions issued by den-
tists working in England, Scotland, Norway and Sweden
over the period 2010–2016 were analysed in this study.
Prescriptions for dental infections accounted on average
for 6–8% of the total prescriptions in Primary care from
these countries. An important caveat of this data is that
in the UK it probably underestimates the actual number
of antibiotic prescriptions since the data source does not
capture private prescriptions, and the number of patients
receiving private treatment is estimated to be around
33% in the UK [21].
All countries show a decline in antibiotic prescriptions
since the start of the analysis period indicating that
Table 2 Number of DDD per 100,000 inhabitants per day (DID100,000) attributed to dental prescriptions in England, Scotland, Norway
and Sweden
Year Antibiotics England Scotland Norway Sweden
DID100,000
2010 (Amxy) – (Phxy) – (Met) No data (70.28)–(2.02) − (10.40) (7.57)–(68.49) – (3.52) (10.28)–(80.37) – (3.29)
(Clin) – (Ery) – (Doxy) No data (0.38)–(4.62) − (1.32) (4.03)–(2.94) –(1.84) (4.15)–(0.54) – (1.36)
(Tet) – (Oxy) – (Azy) No data (0.12)–(0.05) − (0) (0.56)–(0.12) – (1.06) (0.08)–(0) – (0.02)
(Coamxy) – (Spir) No data (0.26)–(0) (0)–(0.17) (0)–(0)
2011 (Amxy) – (Phxy) – (Met) (89.93)–(0.94) – (13.66) (76.39)–(1.99) – (11.35) (7.82)–(67.70) – (3.55) (10.26)–(80.49) – (3.26)
(Clin) – (Ery) – (Doxy) (0.45)–(6.16) – (0.52) (0.34)–(4.67) − (1.43) (4.21)–(2.84) – (1.83) (4.37)–(0.49) – (1.46)
(Tet) – (Oxy) – (Azy) (0.16)–(0.06) – (0.01) (0.14)–(0.05) − (0) (0.43)–(0.06) – (1.20) (0.09)–(0) – (0.02)
(Coamxy) – (Spir) (0.34)–(0) (0.28)–(0) (0)–(0.15) (0)–(0)
2012 (Amxy) – (Phxy) – (Met) (89.45)–(0.76) – (13.56) (79.66)–(1.78) – (11.96) (8.27)–(66.06) – (3.66) (10.16)–(78.05) – (3.27)
(Clin) – (Ery) – (Doxy) (0.42)–(6.03) – (0.49) (0.33)–(4.64) – (1.54) (4.56)–(2.61) – (2.0) (4.21)–(0.40) – (1.51)
(Tet) – (Oxy) – (Azy) (0.13)–(0.05) –(0.04) (0.13)–(0.05) – (0.02) (0.37)–(0) – (1.19) (0.10)–(0) – (0.02)
(Coamxy) – (Spir) (0.42)–(0) (0.20)–(0) (0)–(0.15) (0) – (0)
2013 (Amxy) – (Phxy) – (Met) (87.14)–(0.62) – (13.21) (78.38)–(1.48) – (11.68) (8.88)–(65.37) – (3.78) (8.58)–(74.74) – (3.02)
(Clin) – (Ery) – (Doxy) (0.36)–(5.73) – (0.45) (0.29)–(4.29) – (1.24) (4.79)–(2.53) – (1.82) (3.73)–(0.31) – (1.27)
(Tet) – (Oxy) – (Azy) (0.11)–(0.04) – (0.05) (0.14)–(0.04) – (0.03) (0.34)–(0) – (1.18) (0.07)–(0) – (0.03)
(Coamxy) – (Spir) (0.43)–(0) (0.25)–(0) (0)–(0.13) (0) – (0)
2014 (Amxy) – (Phxy) – (Met) (87.19)–(0.48) – (13.08) (85.35)–(1.23) – (11.03) (9.45)–(65.05) – (3.80) (7.43)–(69.76) – (2.68)
(Clin) – (Ery) – (Doxy) (0.33)–(5.35) – (0.38) (0.24)–(3.84) – (1.09) (5.21)–(2.31) – (1.86) (3.21)–(0.25) – (1.04)
(Tet) – (Oxy) – (Azy) (0.09)–(0.04) – (0.06) (0–09) – (0.02) – (0.02) (0.34)–(0) – (1.09) (0.06)–(0) – (0.03)
(Coamxy) – (Spir) (0.46)–(0) (0.20)–(0) (0)–(0.14) (0) – (0)
2015 (Amxy) – (Phxy) – (Met) (85.04)–(0.37) – (12.46) (85.90)–(0.92) – (9.92) (9.39)–(63.66) – (3.52) (7.37)–(68.33) – (2.51)
(Clin) – (Ery) – (Doxy) (0.30)–(4.85) – (0.35) (0.18)–(3.37) – (1.02) (5.27)–(1.98) – (1.81) (3.18)–(0.24) – (0.96)
(Tet) – (Oxy) – (Azy) (0.07)–(0.03) – (0.06) (0.06)–(0.03) – (0.02) (0.28)–(0) – (0.95) (0.05)–(0) – (0.03)
(Coamxy) – (Spir) (0.44)–(0) (0.16)–(0) (0)–(0.13) (0) – (0)
2016 (Amxy) – (Phxy) – (Met) (80.93)–(0.29) – (11.77) (82.92)–(0.68) – (9.56) (9.52)–(58.65) – (3.39) (6.99)–(66.86) – (2.52)
(Clin) – (Ery) – (Doxy) (0.28)–(4.47) – (0.32) (0.19)–(2.52) – (0.86) (4.58)–(1.81) – (1.37) (3.02)–(0.21) – (0.88)
(Tet) – (Oxy) – (Azy) (0.05)–(0.03) – (0.06) (0.05)–(0.03) – (0.01) (0.27)–(0) – (0.82) (0.04)–(0) – (0.04)
(Coamxy) – (Spir) (0.40)–(0) (0.13)–(0) (0)–(0.11) (0) – (0)
Amxy Amoxicillin, Phxy Phenoxymethyl penicillin, Met Metronidazole, Clin Clindamycin, Ery Erythromycin, Doxy Doxycycline, Tet Tetracycline, Oxy Oxytetracycline,
Azy Azithromycin, Coamxy Co-amoxiclav
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stewardship initiatives in these countries are having an
overall downward effect on prescription volumes. From
2010 to 2016, Sweden dentists reduced their total num-
ber of prescriptions by 19% followed by England 18%,
Scotland 13% and then Norway by 4%. Although the
least reduction of the total number of prescriptions was
in Norway, however, the DID100,000 and number of pre-
scriptions per dentists in Norway are still the lowest for
all antibiotics, except Clindamycin, compared to Eng-
land, Scotland and Sweden. The significantly lower pre-
scribing rates in other Northern European countries
compared to the UK is a pattern observed in other Spe-
cialties [22]. Lower prescribing rates in Norway and
Sweden may also be due to differences in diseases levels
in addition to prescribing habits. However, the findings
reported in our study have several limitations such as,
the UK data only relates to NHS primary care dentistry
and excludes private provision and hospital data. As with
all prescribing, this data takes no account of whether the
prescribing was appropriate or not and does not include
dose, frequency or duration. The results and conclusions
must be interpreted in the context of these limitations.
One of the more marked differences in the antibiotic
prescribing patterns between the UK and Northern
Scandinavian countries is the selection of Amoxicillin
over Phenoxymethyl penicillin. In the UK the British Na-
tional Formulary highlights either Amoxicillin (500 mg
every 8 h in adults for 5 days) or Metronidazole (400mg
every 8 hourly in adults for 3–7 days) [23]. The dose and
duration for Phenoxymethyl penicillin in adults is 500
mg 6 hourly for 5 days. UK professional society guid-
ance, such as the Faculty of General Dental Practice
(FGDP) and the Scottish Dental Clinical Effectiveness
Programme (SDCEP) also highlights the first choice of
Amoxicillin for use in acute dento-alveolar (dental ab-
scess) infections [2, 3]. In Norway and Sweden, the rec-
ommendations for treatment choice for acute dento-
alveolar infections are given in the Norwegian Director-
ate of Health [1] which recommends Phenoxymethyl
penicillin (660 mg every 6 hourly in adults for 5 days)
and in Sweden the recommended regime by the Swedish
Medical Products Agency is 1,6 g Phenoxymethyl peni-
cillin every 8 h for 5–7 days [24]. Prescription of Phenox-
ymethyl penicillin in Norway and Sweden as the first
line of drug to treat infections in outpatients is common
not only in dentistry but also in general medicine for
management of upper respiratory tract infections [1]. In
Norway for example, the prescription of Phenoxymethyl
penicillin contributes to about 70% of the total antibiotic
prescriptions in the country [18].
The narrower spectrum Phenoxymethyl penicillin are
more widely prescribed in Norway and Sweden whilst
the broader spectrum Amoxicillin is largely prescribed
in England and Scotland. The Amoxicillin DID100,000 for
Norway and Sweden is at least 10 times less than that of
England and Scotland. Similar pattern is also found in
other European countries where DID100,000 attributed to
dental prescription of Amoxicillin in Belgium is approxi-
mately 10 times higher than that of Norway and Sweden
[25]. The question arises whether the differences
Table 3 The average DDD per 100,000 inhabitants per day (DID100,000) attributed to dental prescriptions during the study period
England, Scotland, Norway and Sweden
Antibiotics Average of DID100,000 dispensed in the community from 2010 to 2016
Englanda Scotland Norway Sweden
(Amxy) 86.73 79.85 8.70 8.72
(Phxy) 0.58 1.44 65.00 74.09
(Cflxn) 0.27 0.24 0 0
(Cfrdn) 0.04 0.09 0 0
(Coamxy) 0.42 0.21 0 0
(Met) 12.95 10.84 3.60 2.94
(Clin) 0.36 0.24 4.66 3.70
(Ery) 5.43 3.99 2.43 0.35
(Doxy) 0.42 1.21 1.79 1.21
(Tet) 0.10 0.10 0.37 0.07
(Oxy) 0.04 0.04 0.03 0
(Azy) 0.05 0.02 1.07 0.03
(Clary) 0.21 0.10 0.06 0.02
(Spir) 0 0 0.14 0
Amxy Amoxicillin, Phxy Phenoxymethyl penicillin, Cflxn Cefalexin, Cfrdn Cefradine, Coamxy Co-amoxiclav, Met Metronidazole, Clin Clindamycin, Ery Erythromycin,
Doxy Doxycycline, Tet Tetracycline, Oxy Oxytetracycline, Azy Azithromycin, Clary Clarithromycin, Spir Spiramycin
a Data from England is available from 2011 to 2016
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between Scandinavia and the UK in prescription behav-
iour among dentists is because of differences in suscepti-
bility among oral bacteria or because of attitudes toward
antibiotic prescribing influenced by educational curricu-
lum, stewardship programs and national guidelines. Of
further interest is the proportionally higher use of clin-
damycin in Norway and Sweden, in the UK one of the
drivers to reduce prescribing of clindamycin is it’s link
to C. difficile infection. It is unclear why there is a higher
prescription rate for this antibiotic in Norway and
Sweden.
The majority of oral penicillins are absorbed, so that
they yield peak levels 1–2 h after ingestion with approxi-
mately 60 and 75% absorption following oral administra-
tion for Phenoxymethyl penicillin and Amoxicillin,
respectively [26]. Penicillins are bound to proteins (usu-
ally albumin) to varying degrees ranging from 17% for
Amoxicillin to 80% for Pencillin V. Only unbound drug
exerts antibacterial activity, because the bound drug is
not free to interact with penicillin binding proteins.
However, protein binding is a reversible process and it is
possible for bound protein to be desorbed and then re-
leased to interact with bacteria in tissue [26]. Penicillin’s
are well distributed to most areas of the body, and their
levels in areas affected by dental abscesses are sufficient
in the presence of inflammation to inhibit most suscep-
tible bacteria [27].
Phenoxymethyl penicillin and Amoxicillin belong to
the time-dependent killing agents, with a target to main-
tain concentrations greater than the MIC for greater
than or equal to 75% of the dosing interval). Phenoxy-
methyl penicillin, are most active against non-ß-lacta-
mase producing Gram-positive bacteria (viridans group
streptococci, anginosus group streptococci), anaerobes
and selected Gram-negative cocci. Gram positive bac-
teria inhibited by natural pencillins in general are more
susceptible to Phenoxymethyl penicillin than to semisyn-
thetic pencillins like Amoxicillin [28, 29]. Typical MIC’s
for common Gram positive streptococci from dental in-
fections, such as viridans streptococci are 0.01 and
0.05 μg/ml for Phenoxymethyl penicillin and Amoxicillin
[26]. For anginosus streptococci these are invariably sen-
sitive to Phenoxymethyl penicillin and Amoxicillin [30].
Amoxicillin possess the same spectrum as Phenoxy-
methyl penicillin, plus they are more active against
Gram negative cocci and members of the family Entero-
bacteriaceae [31]. Both agents are susceptible to a wide
range of ß-lactamases.
Antibiotic resistance in microbes recovered from the
acute dental abscess has been reported to be increasing
(with the exception of Metronidazole) in some popula-
tions studied over the last few decades [32–35]. Care
must be taken in interpretation of studies due to differ-
ences in details of the identification of isolates, selection
of appropriate breakpoints and their relevance to oral in-
fections and lack of details on MICs (for example, not
all studies report MIC90 data). This is illustrated by re-
ports of resistance rates for Amoxicillin ranging from 9
to 54% of common isolates from acute dental abscesses
[12]. However, analysis of a number of reports does re-
veal a trend that the least susceptible isolates from an
acute abscess are more likely to be black-pigmented Pre-
votella species, such as Prevotella intermedia. Resistance
to macrolides appears to have a higher prevalence in the
‘viridans group streptococci’, anaerobic streptococci and
Prevotella species [36–38]. The prevalence of resistance
to lincosamides, such as clindamycin, is low. For ex-
ample, Kuriyama et al. reported on 664 isolates from
163 patients and found a clindamycin MIC90 of 2 mg/L
for 15 strains of penicillin resistant anaerobic strepto-
cocci, with all the remaining isolates (649) having a clin-
damycin MIC90 less than 0.5 mg/L. Similar low levels of
clindamycin resistance have been found in the UK and
elsewhere [37, 39].
Differences in the prescribing patterns of Metronida-
zole are also markedly different between the UK and
Northern Scandinavian countries. In England and
Scotland prescription of Metronidazole in accounts for
approximately 52–57% of all Metronidazole prescribed
in primary care [40, 41]. In Norway and Sweden, metro-
nidazole prescription by dentists account for 19 and
16%, respectively, of the total metronidazole prescrip-
tion. The driving force for this prescribing pattern is un-
clear, with UK guidance provided in the BNF/FGDP/
SDCEP which recommends Amoxicillin as a first line
agent with clindamycin or clarithromycin as a second
line agent or in patients allergic to penicillins [2, 3, 23].
Metronidazole is advocated (SDCEP) as an alternative
agent in penicillin allergic patients and in the first line
management of necrotising gingivitis and pericoronitis.
Additional guidance (SDCEP) suggests addition of
metronidazole to amoxicillin in cases of severe odonto-
genic infection [3]. The treatment course for Metronida-
zole in the UK is 400 mg every 8 h for 5 days [23]. In
Norway and Sweden the recommendations for prescrib-
ing metronidazole in dental infections is also 400 mg
every 8 h for 5–10 days [1, 24].
The high levels of use of Metronidazole for the man-
agement of dental infections in England and Scotland is
of concern in the context of potential increase in Metro-
nidazole resistance in anaerobic bacteria populations
[42]. This is compounded by poor surveillance systems
in dental infections for either detection of antibiotic re-
sistance to beta-lactams or Metronidazole.
The prescribing levels of the macrolides (clarithromy-
cin/erythromycin) are as expected for their recom-
mended use as second line agents in patients allergic to
penicillins. Spiramycin is an antibiotic belong to the
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macrolide group of antibiotics. It has a spectrum against
aerobic and anaerobic bacteria. This drug is prescribed
by dentists in Norway and not by dentists in England,
Scotland and Sweden, although Norwegian prescription
guidelines do not encourage the use of this drug. The
use of spiramycin as an adjunct to mechanical therapy
for treatment of periodontal infections is recommended
in the Norwegian Pharmaceutical Product Compendium
(Felleskatalogen), which might explain the prescription
of his drug in Norway.
Conclusion
In conclusion, this study has provided an in-sight into
prescribing patterns for bacterial intra-oral infections
managed by general dental practitioners from England
and Scotland with Norway and Sweden. All four coun-
tries demonstrated reduction in overall numbers of
items dispensed with lower prescribing patterns in
Norway and Sweden. Other notable differences in pre-
scribing patterns linked to first line choice of antibiotic
between these countries existed with Phenoxymethyl
penicillin the preferred choice in Scandinavia. There is
some logic in a more widespread adoption of the use of
the narrower spectrum Phenoxymethyl penicillin over
Amoxicillin in the UK as it probably has a lesser impact
on the normal flora without compromising treatment ef-
ficacy. Identification of high levels of Spiramycin pre-
scribing in Norway may serve as a trigger for this
country to review the prescribing guidance for the use of
this antibiotic in managing chronic periodontal disease.
Further work is required to understand the high levels of
metronidazole prescriptions as this element of health-
care accounts for a significant contribution of selection
pressure for the emergence of metronidazole resistance.
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